Immuron Reports Results in Severe Alcoholic Hepatitis Clinical Trial
Immuron Limited - American Depositary Shares (IMRN)
US:NASDAQ Investor Relations:
immuron.com/investor-centre/business-overview
Company Research
Source: GlobeNewswire
MELBOURNE, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the topline results of the clinical study conducted by the TREAT Consortium which was funded by the National Institute of Alcohol Abuse and Alcoholism (NIAAA). The primary objective of the TREAT-003 study was to evaluate the safety and efficacy of IMM-124E at two oral dosage levels as compared with a placebo and provide proof of concept in human subjects for the Mechanism of Action (MoA) in patients with severe alcoholic hepatitis being treated with steroids. The study was conducted at three clinical sites in the USA and supported by a UO1 grant from NIAAA. A total of 57 patients with Severe Alcoholic Hepatitis (SAH) with a Model for End Stage Liver Disease (MELD) Score ranging from 21-28 were enrolled into the clinical st
Show less
Read more
Impact Snapshot
Event Time:
IMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRN alerts
High impacting Immuron Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMRN
News
- Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap EventGlobeNewswire
- Immuron Limited to Present at November 21st Virtual Investor Summit Microcap EventAccesswire
- Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare ConferenceGlobeNewswire
- Immuron Travelan® continued strong sales growthGlobeNewswire
- NMRC Reports Results for Campylobacter Controlled Human Infection Model StudyGlobeNewswire
IMRN
Sec Filings
- 11/18/24 - Form 6-K
- 11/14/24 - Form 6-K
- 10/29/24 - Form 6-K
- IMRN's page on the SEC website